A Phase 2 interventional study of Fp MDPI and FS MDPI in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 10 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-06-12.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.
Among the 147 studies testing fluticasone in Asthma, this one is the 80th largest by enrollment of the 146 interventional ones that give a count, is one of 8 that started in 2013, is one of 25 in phase 2, and was the 97th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 8 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is close to the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 100 across the 146 interventional studies. Of the 130 that completed or were terminated, 68 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 147 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
54 studies in Asthma by Teva Pharmaceutical Industries, Ltd.: none open now, 1 under way, 1 of them phase 3. Of 52 finished, 36 (69%) have results posted.
Among the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd., this one is the 36th largest by enrollment of the 51 interventional ones that give a count, is one of 8 that started in 2013, is one of 11 in phase 2, and was the 21st registered.
Teva Pharmaceutical Industries, Ltd.’s Asthma studies by the year they started, since 2003.
2 of the studies testing fluticasone in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07664527University of Wisconsin, MadisonNovel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 147 studies testing fluticasone in Asthma, from their registry updates:
Among Teva Pharmaceutical Industries, Ltd.’s 54 in Asthma:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the dose response, efficacy, and safety of 4 different doses of salmeterol Spiromax (6.25, 12.5, 25, and 50 mcg) each combined with a fixed dose of fluticasone propionate (100 mcg) delivered as Fluticasone/Salmeterol Spiromax® Inhalation Powder (FS Spiromax) when administered as a single dose in subjects 12 years of age and older with persistent asthma.
This was a multicenter, randomized, double-blind and open-label active-controlled, single-dose, 6 period crossover, dose-ranging study conducted in male and female subjects ages 12 years and older with persistent asthma.
Fluticasone propionate multidose dry powder inhaler (Fp MDPI) 50 mcg was provided (to replace the subject's current inhaled corticosteroid (ICS)) throughout the 14 day run-in period and each of the washout periods between treatments. Subjects were instructed to administer 2 inhalations of Fp MDPI 50 mcg (100 mcg total dose) twice daily during the run-in and washout periods. All other medications for the treatment of asthma were discontinued at or prior to the screening visit.
A short-acting β2-adrenergic agonist (SABA), salbuterol HFA, MDI, was provided (to replace the subject's current rescue medication) for symptomatic relief of asthma symptoms in each the run-in, treatment, and washout periods.
Treatment period lasted 5 weeks with a 5 to 7 day washout between each of the six single dose treatments:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects inhaled a single dose of 100 mcg fluticasone propionate and 6.25 mcg salmeterol xinafoate.
Drug: FS MDPI · Drug: Albuterol
Subjects inhaled a single dose of 100 mcg fluticasone propionate and 12.5 mcg salmeterol xinafoate.
Drug: FS MDPI · Drug: Albuterol
Subjects inhaled a single dose of 100 mcg fluticasone propionate and 25 mcg salmeterol xinafoate.
Drug: FS MDPI · Drug: Albuterol
Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate.
Drug: FS MDPI · Drug: Albuterol
Subjects inhaled a single dose of 100 mcg fluticasone propionate.
Drug: Fp MDPI · Drug: Albuterol
Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate. This arm is the only arm which is open-label because the inhaler device was different than the MDPI used in the other treatment arms.
Drug: Advair Diskus · Drug: Albuterol
Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. Fp at 100 mcg was an active comparator (single dose). Further, participants were instructed to administer two inhalations of Fp MDPI 50 mcg twice daily (100 mcg total dose) during the Run-in (to replace the participant's current inhaled corticosteroid) and Washout Periods between treatments.
Also known as: fluticasone propionate, inhaled corticosteroid, Fp Spiromax
FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. The fluticasone propionate component was a fixed dose of 100 mcg. The salmeterol xinofoate dosage varied: 6.25, 12.5, 25 or 50 mcg.
Also known as: fluticasone propionate, inhaled corticosteroid, Salmeterol xinafoate, β2 adrenoceptor agonist, FS Spiromax
ADVAIR DISKUS (100/50 mcg fluticasone propionate/salmeterol xinafoate) consists of a dry powder formulation of fluticasone propionate and salmeterol xinafoate in a lactose excipient. The dry powder is contained within individual blisters on a double foil strip within the device. Activation of the device opens a single blister of medication which is then dispersed into the air-stream by patient inhalation.
Also known as: fluticasone propionate, inhaled corticosteroid, salmeterol xinafoate, β2 adrenoceptor agonist
Albuterol (Pro-Air) hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
Also known as: Pro-Air, short-acting β2-adrenergic agonists
Standardized Baseline-Adjusted Area Under the Curve For Forced Expiratory Volume In 1 Second Over 12 Hours Post-dose (FEV1 AUC0-12)
Standardized baseline-adjusted FEV1 AUC0-12 was defined as the area under the curve for baseline-adjusted FEV1 measurements from the predose to 12 hours postdose time points using the trapezoidal rule based on actual (not scheduled) time of measurement and was standardized by dividing the actual time of last non-missing FEV1 measurement. Baseline-adjusted FEV1 was calculated as postdose FEV1 after subtracting period-specific baseline FEV1. The period-specific baseline FEV1 was measured at predose within 5 minutes of AM dose administration at each treatment visit. If that value was missing, then FEV1 measured at 30 minutes predose was used as the period-specific baseline.
Time frame: Pre-dose: 30 minutes prior, within 5 minutes of dose. Post-dose: 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours
Change From Baseline at 12 Hours Post-Dose in Forced Expiratory Volume in One Second (FEV1) By Treatment
The secondary efficacy variable was the change from period-specific baseline in FEV1 at 12 hours, calculated as FEV1 measured at 12 hours postdose after subtracting period-specific baseline FEV1 at each treatment period. The period-specific baseline FEV1 was measured at predose within 5 minutes of AM dose administration at each treatment visit. If that value was missing, then FEV1 measured at 30 minutes predose was used as the period-specific baseline.
Time frame: Pre-dose: 30 minutes prior, within 5 minutes of dose. Post-dose: 12 hours
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t) of Salmeterol
Blood samples for measurement of plasma SAL concentrations were obtained during each treatment visit (subjects 18 years of age and older only) and pharmacokinetic parameters were derived. The primary pharmacokinetic parameters were AUC0-t and Cmax for Salmeterol.
Time frame: Predose (0), and at 5, 10, 15 and 30 minutes, 1, 1.5, 2, 3, 4, 8, and 12 hours postdose
Maximum Observed Plasma Concentration (Cmax) of Salmeterol
Blood samples for measurement of plasma SAL concentrations were obtained during each treatment visit (subjects 18 years of age and older only) and pharmacokinetic parameters were derived. The primary pharmacokinetic parameters were AUC0-t and Cmax for Salmeterol.
Time frame: Predose (0), and at 5, 10, 15 and 30 minutes, 1, 1.5, 2, 3, 4, 8, and 12 hours postdose
Time of Maximum Observed Plasma Concentration (Tmax) of Salmeterol
Blood samples for measurement of plasma SAL concentrations were obtained during each treatment visit (subjects 18 years of age and older only) and pharmacokinetic parameters were derived.
Time frame: Predose (0), and at 5, 10, 15 and 30 minutes, 1, 1.5, 2, 3, 4, 8, and 12 hours postdose
Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
TEAEs were recorded during each double-blind treatment. In addition, at the end of each treatment, patients continued to use 2 inhalations of Fp MDPI 50 mcg (100 mcg total dose) twice daily, so adverse events during this treatment were assigned to Fp MDPI 50 mcg. An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical in
Time frame: Day 1 up to Day 35
A total of 105 subjects with asthma were screened for this study. Of the 105 subjects screened, 82 subjects at 10 investigational sites in the US met entry criteria and were considered to be eligible to enter the run-in period.
| Milestone | All Participants |
|---|---|
| Started | 72 |
| Received fp mdpi 100 mcg | 67 |
| Received fs mdpi 100/6.25 mcg | 68 |
| Received fs mdpi 100/12.5mcg | 69 |
| Received fs mdpi 100/25 mcg | 67 |
| Received fs mdpi 100/50 mcg | 68 |
| Received advair diskus 100/50 mcg | 66 |
| Completed | 65 |
| Not completed | 7 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Other | 1 |
Standardized baseline-adjusted FEV1 AUC0-12 was defined as the area under the curve for baseline-adjusted FEV1 measurements from the predose to 12 hours postdose time points using the trapezoidal rule based on actual (not scheduled) time of measurement and was standardized by dividing the actual time of last non-missing FEV1 measurement. Baseline-adjusted FEV1 was calculated as postdose FEV1 after subtracting period-specific baseline FEV1. The period-specific baseline FEV1 was measured at predose within 5 minutes of AM dose administration at each treatment visit. If that value was missing, then FEV1 measured at 30 minutes predose was used as the period-specific baseline.
| mL | Fp MDPI 100 mcg | FS MDPI 100/6.25 mcg | FS MDPI 100/12.5mcg | FS MDPI 100/25 mcg | FS MDPI 100/50 mcg | Advair Diskus 100/50 mcg |
|---|---|---|---|---|---|---|
| Standardized Baseline-Adjusted Area Under the Curve For Forced Expiratory Volume In 1 Second Over 12 Hours Post-dose (FEV1 AUC0-12) | 52.13 ± 38.071 | 203.84 ± 38.072 | 248.98 ± 38.025 | 279.69 ± 38.121 | 303.43 ± 38.062 | 245.56 ± 38.148 |
The secondary efficacy variable was the change from period-specific baseline in FEV1 at 12 hours, calculated as FEV1 measured at 12 hours postdose after subtracting period-specific baseline FEV1 at each treatment period. The period-specific baseline FEV1 was measured at predose within 5 minutes of AM dose administration at each treatment visit. If that value was missing, then FEV1 measured at 30 minutes predose was used as the period-specific baseline.
| mL | Fp MDPI 100 mcg | FS MDPI 100/6.25 mcg | FS MDPI 100/12.5mcg | FS MDPI 100/25 mcg | FS MDPI 100/50 mcg | Advair Diskus 100/50 mcg |
|---|---|---|---|---|---|---|
| Change From Baseline at 12 Hours Post-Dose in Forced Expiratory Volume in One Second (FEV1) By Treatment | 11.53 ± 29.058 | 128.49 ± 29.109 | 170.51 ± 28.990 | 209.85 ± 29.127 | 238.30 ± 28.988 | 170.54 ± 29.230 |
Blood samples for measurement of plasma SAL concentrations were obtained during each treatment visit (subjects 18 years of age and older only) and pharmacokinetic parameters were derived. The primary pharmacokinetic parameters were AUC0-t and Cmax for Salmeterol.
| pg*hr/mL | Fp MDPI 100 mcg | FS MDPI 100/6.25 mcg | FS MDPI 100/12.5mcg | FS MDPI 100/25 mcg | FS MDPI 100/50 mcg | Advair Diskus 100/50 mcg |
|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t) of Salmeterol | — | 32.8 ± 20.98 | 69.9 ± 35.36 | 133.5 ± 63.13 | 309.3 ± 143.43 | 173.5 ± 106.59 |
Blood samples for measurement of plasma SAL concentrations were obtained during each treatment visit (subjects 18 years of age and older only) and pharmacokinetic parameters were derived. The primary pharmacokinetic parameters were AUC0-t and Cmax for Salmeterol.
| pg/mL | Fp MDPI 100 mcg | FS MDPI 100/6.25 mcg | FS MDPI 100/12.5mcg | FS MDPI 100/25 mcg | FS MDPI 100/50 mcg | Advair Diskus 100/50 mcg |
|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Salmeterol | — | 16.0 ± 8.86 | 35.8 ± 20.25 | 67.5 ± 34.71 | 154.5 ± 80.28 | 42.3 ± 19.28 |
Blood samples for measurement of plasma SAL concentrations were obtained during each treatment visit (subjects 18 years of age and older only) and pharmacokinetic parameters were derived.
| hours | Fp MDPI 100 mcg | FS MDPI 100/6.25 mcg | FS MDPI 100/12.5mcg | FS MDPI 100/25 mcg | FS MDPI 100/50 mcg | Advair Diskus 100/50 mcg |
|---|---|---|---|---|---|---|
| Time of Maximum Observed Plasma Concentration (Tmax) of Salmeterol | — | 0.1 (0.1 to 12.1) | 0.1 (0.1 to 2.0) | 0.1 (0.1 to 2.0) | 0.1 (0.1 to 1.5) | 0.5 (0.1 to 2.0) |
TEAEs were recorded during each double-blind treatment. In addition, at the end of each treatment, patients continued to use 2 inhalations of Fp MDPI 50 mcg (100 mcg total dose) twice daily, so adverse events during this treatment were assigned to Fp MDPI 50 mcg. An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical in
| Participants | Fp MDPI 100 mcg | FS MDPI 100/6.25 mcg | FS MDPI 100/12.5mcg | FS MDPI 100/25 mcg | FS MDPI 100/50 mcg | Advair Diskus 100/50 mcg | Fp MDPI 50 mcg X 2 BID |
|---|---|---|---|---|---|---|---|
| Any adverse event | 2 | 2 | 3 | 1 | 1 | 3 | 17 |
| Severe adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Treatment-related adverse event | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| Deaths | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other serious adverse events | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrawn from treatment due to AE | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Collected over Day 1 to Day 35. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fp MDPI 100 mcg | 0/67 (0%) | 0/67 (0%) | 0/67 (0%) |
| FS MDPI 100/6.25 mcg | 0/68 (0%) | 0/68 (0%) | 0/68 (0%) |
| FS MDPI 100/12.5mcg | 0/69 (0%) | 0/69 (0%) | 0/69 (0%) |
| FS MDPI 100/25 mcg | 0/67 (0%) | 0/67 (0%) | 0/67 (0%) |
| FS MDPI 100/50 mcg | 0/68 (0%) | 0/68 (0%) | 0/68 (0%) |
| Advair Diskus 100/50 mcg | 0/66 (0%) | 0/66 (0%) | 0/66 (0%) |
| Fp MDPI 50 mcg X 2 BID | 0/72 (0%) | 0/72 (0%) | 4/72 (5.6%) |
| Event | Fp MDPI 100 mcg | FS MDPI 100/6.25 mcg | FS MDPI 100/12.5mcg | FS MDPI 100/25 mcg | FS MDPI 100/50 mcg | Advair Diskus 100/50 mcg | Fp MDPI 50 mcg X 2 BID |
|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 0/67 | 0/68 | 0/69 | 0/67 | 0/68 | 0/66 | 4/72 |
Intent-to-Treat population
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 42.5 ± 13.87 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 37 |
| Male | 35 |
| Race/Ethnicity, Customized(Participants) | All Participants |
|---|---|
| White | 64 |
| Black | 7 |
| Other | 1 |
| Weight(kg) | All Participants |
|---|---|
| Mean | 79.2 ± 14.17 |
| Height(cm) | All Participants |
|---|---|
| Mean | 170.0 ± 9.76 |
| Body Mass Index(kg/m^2) | All Participants |
|---|---|
| Mean | 27.3 ± 3.35 |
The record gives a start of Jan 2013, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 3 years 10 months after primary completion. A results delay was requested in Mar 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone
Teva Branded Pharmaceutical Products R&D, Inc. →